Overview

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Status:
Active, not recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With R/R B-NHL
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.